{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:04:32Z","timestamp":1795122272232,"version":"4.10.3"},"reference-count":28,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Immune effector cell\u2013associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2\/2 vedolizumab; 1\/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018853","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T18:55:04Z","timestamp":1775847304000},"page":"4495-4507","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Diagnosis and management of immune effector cell\u2013associated enterocolitis after ciltacabtagene autoleucel"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-116X","authenticated-orcid":false,"given":"Kenneth J. C.","family":"Lim","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6335-7312","authenticated-orcid":false,"given":"Hee Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"2Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongming Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"2Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6166-6661","authenticated-orcid":false,"given":"Adam","family":"Bledsoe","sequence":"additional","affiliation":[{"name":"3Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[{"name":"4Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Dooley","sequence":"additional","affiliation":[{"name":"6Department of Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[{"name":"6Department of Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Hwa","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haily","family":"Stephens","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Tan","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1050-922X","authenticated-orcid":false,"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Geyer","sequence":"additional","affiliation":[{"name":"6Department of Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"2Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"name":"5Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8882-5579","authenticated-orcid":false,"given":"Navreet","family":"Chowla","sequence":"additional","affiliation":[{"name":"3Division of Gastroenterology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"2","key":"2026071409571115300_bib1","first-page":"71.e1","article-title":"Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data","volume":"31","author":"Ellithi","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026071409571115300_bib2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"2026071409571115300_bib3","article-title":"Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma","author":"Lim","year":"2026;16(1):18","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026071409571115300_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","article-title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"14","author":"Fortuna","year":"2024","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026071409571115300_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMoa2411507","article-title":"CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53","volume":"392","author":"Perica","year":"2025","journal-title":"N Engl J Med"},{"issue":"22","key":"2026071409571115300_bib6","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","article-title":"Indolent CD4+ CAR T-cell lymphoma after cilta-cel CAR T-cell therapy","volume":"390","author":"Ozdemirli","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"2026071409571115300_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"key":"2026071409571115300_bib8","unstructured":"National Cancer Institute Division of Cancer Treatment and Diagnosis. Common Terminology Criteria for Adverse Events (CTCAE). 2017. Accessed 15 April 2025. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40."},{"issue":"24","key":"2026071409571115300_bib9","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026071409571115300_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026071409571115300_bib10","unstructured":"mSMART\n          . The risk adapted approach to management of multiple myeloma and related disorders: management of CAR-T associated cytokine release syndrome (CRS), neurotoxicity, and cytopenias. 2025. Accessed 15 April 2025. https:\/\/www.msmart.org\/mm-treatment-guidelines."},{"issue":"4","key":"2026071409571115300_bib11","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1053\/j.gastro.2020.08.063","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"2026071409571115300_bib12","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"issue":"suppl 1","key":"2026071409571115300_bib13","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1182\/blood-2025-2392","article-title":"Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma","volume":"146","author":"Blumenberg","year":"2025","journal-title":"Blood"},{"issue":"4","key":"2026071409571115300_bib14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026071409571115300_bib15","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.it.2017.10.006","article-title":"Do long-lived plasma cells maintain a healthy microbiota in the gut?","volume":"39","author":"Jahnsen","year":"2018","journal-title":"Trends Immunol"},{"key":"2026071409571115300_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcv.2018.05.004","article-title":"Chronic sequelae and severe complications of norovirus infection: A systematic review of literature","volume":"105","author":"Petrignani","year":"2018","journal-title":"J Clin Virol"},{"issue":"8","key":"2026071409571115300_bib17","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/jmv.21217","article-title":"Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus","volume":"80","author":"Ludwig","year":"2008","journal-title":"J Med Virol"},{"issue":"11","key":"2026071409571115300_bib18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1182\/blood.2021015019","article-title":"DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS","volume":"140","author":"Herek","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026071409571115300_bib19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s43018-025-01072-4","article-title":"A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma","volume":"7","author":"Pilcher","year":"2026","journal-title":"Nat Cancer"},{"key":"2026071409571115300_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: Mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2026071409571115300_bib21","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fimmu.2013.00163","article-title":"The role of regulatory T cells in the biology of graft versus host disease","volume":"4","author":"Beres","year":"2013","journal-title":"Front Immunol"},{"issue":"1","key":"2026071409571115300_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","article-title":"Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies","volume":"14","author":"Tao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"12","key":"2026071409571115300_bib24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"2026071409571115300_bib25","doi-asserted-by":"crossref","first-page":"100050","DOI":"10.1016\/j.modpat.2022.100050","article-title":"A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma","volume":"36","author":"Zhang","year":"2023","journal-title":"Mod Pathol"},{"key":"2026071409571115300_bib26","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/978-1-61779-166-6_24","article-title":"T-cell homing to the gut mucosa: general concepts and methodological considerations","volume":"757","author":"De Calisto","year":"2012","journal-title":"Methods Mol Biol"},{"key":"2026071409571115300_bib27","doi-asserted-by":"crossref","first-page":"612830","DOI":"10.3389\/fcell.2021.612830","article-title":"Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases","volume":"9","author":"Luzentales-Simpson","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2026071409571115300_bib28","doi-asserted-by":"crossref","first-page":"1149450","DOI":"10.3389\/fonc.2023.1149450","article-title":"Case report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma","volume":"13","author":"Zundler","year":"2023","journal-title":"Front Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4495\/2530104\/blooda_adv-2025-018853-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/13\/4495\/2530104\/blooda_adv-2025-018853-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:57:24Z","timestamp":1784037444000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/13\/4495\/567654\/Diagnosis-and-management-of-immune-effector-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018853","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,14]]},"published":{"date-parts":[[2026,6,25]]}}}